Voyager Therapeutics, Inc.
VYGR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001640266
No open-market purchases or sales by Voyager Therapeutics, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $122.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 16, 2026
- $101.4M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 137
- 13F valueReported value at the end of Q2 2026
- $122.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $40.4M
- −49.5% year over year
- Net income, FY2025
- -$119.7M
- No comparable prior period
- Free cash flow, FY2025
- -$135.1M
- No comparable prior period
- Revenue, Q3 FY2026
- $4.01M
- −70.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $119.7M (296.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.38M
- Shares sold short
- Change
- +738.7K
- +20.3% vs. previous
- Days to cover
- 4.10
- At average daily volume
Superinvestors holding VYGR, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VYGR at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Voyager Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2026 (view filing) | Apr 2 | 1 day | Sandrock AlfredPresident and CEO | SSale | −11.5K | $3.87 | −$44.5K | −2.4%472.5K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Swartz RobinCOO & CBO | SSale | −6.46K | $3.77 | −$24.3K | −3.1%199.7K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Sandrock AlfredPresident and CEO | SSale | −14.2K | $3.79 | −$53.8K | −2.8%484.1K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Jorgensen Nathan D.Chief Financial Officer | SSale | −4.67K | $3.77 | −$17.6K | −3.0%151.4K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Carter Todd AlfredChief Scientific Officer | SSale | −4.17K | $3.76 | −$15.7K | −2.8%145.7K after | 10b5-1 |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Swartz RobinCOO & CBO | SSale | −3.88K | $3.44 | −$13.4K | −1.8%206.2K after | 10b5-1 |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Carter Todd AlfredChief Scientific Officer | SSale | −3.30K | $3.44 | −$11.4K | −2.2%149.9K after | 10b5-1 |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Sandrock AlfredPresident and CEO | SSale | −11.7K | $3.41 | −$40.0K | −2.3%498.3K after | 10b5-1 |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Swartz RobinCOO & CBO | SSale | −4.57K | $3.85 | −$17.6K | −2.1%210.1K after | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Sandrock AlfredPresident and CEO | SSale | −12.2K | $3.78 | −$46.1K | −2.3%510.0K after |
Top 10 13F holders, Q2 2026
See all 137 holdersThe largest institutional positions in Voyager Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,172,063 | $18.1M | 0.00% | −396,318−7.1% | Reduced |
| Millennium Management LLC | 4,442,951 | $15.6M | 0.01% | +1,014,380+29.6% | Added |
| Armistice Capital, LLC | 3,436,000 | $12.0M | 0.33% | −64,000−1.8% | Reduced |
| Vestal Point Capital, LP | 2,625,000 | $9.19M | 0.21% | −377,936−12.6% | Reduced |
| Vanguard Capital Management LLC | 2,345,674 | $8.21M | 0.00% | +62,421+2.7% | Added |
| Geode Capital Management, LLC | 1,330,492 | $4.66M | 0.00% | +280,514+26.7% | Added |
| Opaleye Management Inc. | 1,185,000 | $4.15M | 0.38% | +35,000+3.0% | Added |
| State Street Corp | 1,076,422 | $3.77M | 0.00% | +128,196+13.5% | Added |
| Two Sigma Investments, LP | 948,517 | $3.32M | 0.00% | +332,857+54.1% | Added |
| Dimensional Fund Advisors LP | 838,184 | $2.93M | 0.00% | −37,384−4.3% | Reduced |
Holders of 5% or more of VYGR
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Voyager Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 13G/A | 8.65%4.80M shares | – | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
| Integrated Core Strategies (US) LLC | 13G/A | 7.40%4.44M shares | +1.30 ppfrom 6.10% | Jan 26, 20262 filings | Jul 31, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.40%3.53M shares | – | Apr 24, 20251 filing | Apr 24, 2025 | SEC |
| Armistice Capital, LLC | 13G | 6.28%3.87M shares | +5.02 ppfrom 1.26% | Feb 16, 202113 filings | Nov 16, 2026 | SEC |